Tysabri revenues were up 23% to $245.2 million in the quarter, offsetting revenue loss from legacy products including Azactam, Prialt, Maxipime and Skelaxin, which contributed $38.7 million in 1Q10.
Revenue from the BioNeurology business was up 7% for the year boosted by Tysabri sales, while revenue from Elan Drug Technologies (EDT) fell due to reduced revenue from Maxipime, Azactam and Prialt.